Lipocine

LPCN · NASDAQ

$1.62+$0.01 (+0.62%)TodayMarket closed · Oct 21, 5:17 AM ET

Prev close $1.61

LPCN analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform0
Sell0

12-month price target · 4 analysts

Average $5.10 (+214.8% upside)

Low: $4.04
Now: $1.62
High: $6.30

Upgrades and downgrades

The latest rating actions, newest first

LPCN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 21, 2026	Maintains	Neutral	$4.00	40%
HC Wainwright & Co.	Apr 6, 2026	Downgrade	Buy → Neutral	—	40%
HC Wainwright & Co.	Jan 21, 2026	Maintains	Buy	$7.00 → $15.00	40%
HC Wainwright & Co.	Nov 13, 2025	Maintains	Buy	$8.00 → $7.00	40%

The case for and against

Updated May 5, 2026

Bull case

Lipocine is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of oral delivery solutions for existing drugs, with its lead product candidate TLANDO showing promising results in its Phase 3 PPD trial. The company's strong financials, including a net loss of $3.2M and total revenue of $0.1M in the 3Q25, suggest its ability to continue its research and development efforts. With its continued progress and potential in the emerging treatment market for postpartum depression, Lipocine's stock has a positive outlook for growth in the future.

Bear case

Lipocine is a clinical-stage biopharmaceutical company that is heavily reliant on its proprietary drug delivery technology to drive its future growth. However, the company has a limited pipeline and a significant portion of its revenue comes from developing products for corporate partners, making it vulnerable to collaboration setbacks. Additionally, Lipocine has a history of incurring losses and its current cash reserves are significantly lower than its long-term debt, suggesting potential financial difficulties in the future.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.